These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3746580)

  • 61. [Sterilization and stability of idoxuridine containing ophthalmic solutions].
    Backer ET; van de Langerijt JJ
    Pharm Weekbl; 1966 Jun; 101(22):489-96. PubMed ID: 5940164
    [No Abstract]   [Full Text] [Related]  

  • 62. [Advances in the field of galenics (1965 to 1967)].
    Chalabala M; Malý J; Burelová A
    Pharmazie; 1969 Feb; 24(2):65-86. PubMed ID: 4891843
    [No Abstract]   [Full Text] [Related]  

  • 63. Sterile holding tank system.
    Pauli WA; Grimes TL; Fonner DE; Griffin JC
    Bull Parenter Drug Assoc; 1975; 29(4):163-8. PubMed ID: 1131460
    [No Abstract]   [Full Text] [Related]  

  • 64. The "bubble point" for validation of drug release or simulated absorption tests for ointments.
    Realdon N; Tagliaboschi A; Perin F; Ragazzi E
    Pharmazie; 2005 Dec; 60(12):910-6. PubMed ID: 16398267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Accelerated method of preparing tiger ointment and its analysis].
    Kotenko OM
    Farm Zh; 1975; (5):91-2. PubMed ID: 1083811
    [No Abstract]   [Full Text] [Related]  

  • 66. [Treatment of glaucoma simplex using Syncarpin. Comparative studies on the effect of ophthalmic solution and ointment].
    Knapp E
    Klin Monbl Augenheilkd; 1970; 156(1):83-6. PubMed ID: 5438847
    [No Abstract]   [Full Text] [Related]  

  • 67. [Advances in pharmaceutical technology in 1966-1967. II. Drugs and pharmaceutical preparations].
    Chalabala M; Malý J; Burelová A; Starha L; Heliová M; Rak J; Rehula A
    Cesk Farm; 1968 Nov; 17(9):450-61. PubMed ID: 4888356
    [No Abstract]   [Full Text] [Related]  

  • 68. [The use of asbestos filter beds in the production of sterile and pyrogen free solutions].
    Kaden H
    Pharmazie; 1975 Nov; 30(11):752-3. PubMed ID: 1219784
    [No Abstract]   [Full Text] [Related]  

  • 69. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension.
    Scoper SV; Kabat AG; Owen GR; Stroman DW; Kabra BP; Faulkner R; Kulshreshtha AK; Rusk C; Bell B; Jamison T; Bernal-Perez LF; Brooks AC; Nguyen VA
    Adv Ther; 2008 Feb; 25(2):77-88. PubMed ID: 18309465
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Formulation design and development of parenteral suspensions.
    Akers MJ; Fites AL; Robison RL
    J Parenter Sci Technol; 1987; 41(3):88-96. PubMed ID: 3612415
    [No Abstract]   [Full Text] [Related]  

  • 71. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 72. [Determination of metallic particles in ophthalmic ointments].
    Cavatorta L; Romaniello E; Allievi R
    Boll Chim Farm; 1968 Nov; 107(11):721-5. PubMed ID: 5729799
    [No Abstract]   [Full Text] [Related]  

  • 73. [Contributions to the liberation of drugs from suspension ointments. Part 19: Studies on the interactions of hydroxyquinoline (salts) with ointment components (author's transl)].
    Heber B; Horsch W
    Pharmazie; 1982 Apr; 37(4):277-9. PubMed ID: 7100252
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of preservative systems in opthalmic suspension of polymyxin B and dexamethasone by linear regression.
    Bou-Chacra NA; Pinto TJ; Kaneko TM
    Pharmazie; 2007 Mar; 62(3):199-204. PubMed ID: 17416196
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Stability of aqueous solutions of aureomycin hydrochloride in the presence of some substances applied in ophthalmic drops].
    Olszewski Z; Grabowska-Bochenek J
    Acta Pol Pharm; 1967; 24(5):505-9. PubMed ID: 6062758
    [No Abstract]   [Full Text] [Related]  

  • 76. Bioluminescence for USP sterility testing of pharmaceutical suspension products.
    Bussey DM; Tsuji K
    Appl Environ Microbiol; 1986 Feb; 51(2):349-55. PubMed ID: 3954348
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Root Cause Analysis, Part 2: STERILE COMPOUNDING.
    Cabaleiro J; Jackson K
    Int J Pharm Compd; 2016; 20(2):99-104. PubMed ID: 27323421
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Landmark article: Air-suspension technique of coating drug particles. 1959.
    Wurster DE
    J Am Pharm Assoc (2003); 2012; 52(5):707-10. PubMed ID: 23023851
    [No Abstract]   [Full Text] [Related]  

  • 79. Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions.
    Allen LV
    Int J Pharm Compd; 2016; 20(5):399-404. PubMed ID: 28339375
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Data on the stability of vitamin A in some ointments and ophthalmic solutions].
    Gaiţă G; Verbuţă A; Oiţă N
    Rev Med Chir Soc Med Nat Iasi; 1976; 80(3):441-3. PubMed ID: 1024241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.